COVID-19: Page 2
-
Medtech sector poised for growth as healthcare staffing tops pre-COVID levels: KeyBanc
The analysts are “leaning into increased medtech exposure” after determining that several challenges that have constrained the industry are easing.
By Nick Paul Taylor • April 13, 2023 -
FDA sets end date for raft of COVID-related shortages that began early in pandemic
Shortages of home-use ventilators and clinical sample concentrators are expected to continue.
By Nick Paul Taylor • March 20, 2023 -
QuidelOrtho COVID test is first to win FDA nod via premarket review
Special controls instituted by the FDA as part of the De Novo assessment pave the way for other tests to come to market without pandemic-era Emergency Use Authorization.
By Nick Paul Taylor • March 9, 2023 -
FDA authorizes first at-home flu-COVID-19 combination test days after its developer files for bankruptcy
Lucira filed for bankruptcy protection last week, saying the “protracted” authorization process caused it to miss out on test sales in the 2022 to 2023 flu season.
By Nick Paul Taylor • Feb. 27, 2023 -
Henry Schein Q4 profit drops, hurt by falling sales of COVID test kits, PPE
Flu and COVID-19 cases increased appointment cancellations and added to staffing shortages in the quarter.
By Nick Paul Taylor • Feb. 17, 2023 -
Baxter, Abbott, Thermo Fisher among medtech firms cutting jobs on supply issues, slide in testing
"What COVID gave to diagnostics companies, COVID taketh away now that the virus is endemic,” said one analyst.
By Susan Kelly • Updated Feb. 13, 2023 -
Thermo Fisher cuts additional 230 jobs in California
The job reductions come amid a downturn in demand for COVID-19 tests.
By Susan Kelly • Updated Feb. 10, 2023 -
Medtech earnings highlights: Easing of macro pressures, accelerated growth in 2023
Still, the latest round of quarterly results show that hospital staffing and supply chain remain a challenge.
By Nick Paul Taylor • Feb. 6, 2023 -
Quest cuts 2023 COVID tests forecast amid continued slump in demand; Q4 profit plunges
The company performed 1.2 million molecular tests in the fourth quarter, down from 1.9 million in the third quarter and 5.4 million one year ago.
By Nick Paul Taylor • Feb. 3, 2023 -
FDA weighs shift in COVID vaccination strategy
Agency scientists are proposing to update COVID shots once a year to match circulating coronavirus strains, as well as simplifying current vaccination regimens.
By Ned Pagliarulo • Jan. 23, 2023 -
Investors hand Vaxxas $23M to support trial of needle-free COVID-19 vaccine
With support from the Gates Foundation, the needle-free technology could get more people vaccinated and avoid cold-chain issues.
By Nick Paul Taylor • Dec. 12, 2022 -
Retrieved from Medtronic on September 19, 2022
Excess deaths to continue constraining recovery of TAVR market in 2023: Goldman
Hospital staffing shortages and excess deaths among seniors are expected to slow the recovery of structural heart procedures, Goldman Sachs analysts said.
By Nick Paul Taylor • Dec. 7, 2022 -
18M projected to lose Medicaid coverage at end of COVID-19 emergency
Many people who are currently enrolled in Medicaid will transition to other coverage, but 3.8 million people will completely lose insurance, according to the Robert Wood Johnson Foundation.
By Susan Kelly • Dec. 6, 2022 -
The 10 biggest medtech stories of 2022
MedTech Dive reporting this year has explored how companies maintained momentum even amid supply shortages and rising inflation rates.
By MedTech Dive staff • Dec. 3, 2022 -
Masimo’s pulse oximeter has no significant racial bias, study finds
The company said the result reflects its use of four additional signal processing engines that cut the impact of factors including skin pigmentation.
By Nick Paul Taylor • Nov. 28, 2022 -
‘Tripledemic’ concerns spur FDA to issue emergency authorization for flu-COVID-19 combination test
Experts have warned “a viral hurricane is making landfall” as cases of RSV, influenza and COVID-19 rise simultaneously.
By Nick Paul Taylor • Nov. 23, 2022 -
Q3 Earnings Wrap: Bumpy time for medtech with inflation, FX, supply woes
Macroeconomic pressures were a persistent theme for the industry, with workforce reductions a part of the fallout for some companies.
By Susan Kelly • Nov. 21, 2022 -
How Labcorp, Abbott, BD, Siemens plan to expand home testing market
As demand wanes for COVID-19 testing, businesses see an opportunity in direct-to-consumer diagnostics.
By Elise Reuter • Nov. 16, 2022 -
Roche starts OTC sales of COVID-19 test in first push into US market
CVS, Amazon and the Optum Store are stocking the product, rebranded Pilot.
By Nick Paul Taylor • Nov. 11, 2022 -
Retrieved from Siemsens Website on July 01, 2022
Siemens Healthineers beats sales forecasts on imaging demand as diagnostic pressures prompt restructuring
Siemens Healthineers is revamping its diagnostics unit after concluding that “external headwinds [are] outweighing operational improvements.”
By Nick Paul Taylor • Nov. 9, 2022 -
Hologic quarterly sales beat forecast even as demand for COVID tests wanes
The company expects its surgical and breast health businesses to rebound in fiscal 2023.
By Nick Paul Taylor • Nov. 1, 2022 -
Labcorp lowers 2022 forecasts after Q3 profit falls on labor costs, declining COVID-19 revenue
To help reboot earnings, a planned spinoff of the Clinical Development business has been accelerated and the company will continue to acquire testing facilities from hospital systems across the country.
By Peter Green • Oct. 27, 2022 -
Thermo Fisher raises full-year revenue forecast after posting extra $200M in COVID-19 test sales in Q3
With COVID test sales expected to fall to an “endemic run rate level” in the fourth quarter, the company expects growth to come from the pharma services and bioproduction units.
By Nick Paul Taylor • Oct. 27, 2022 -
Abbott Q3 device sales slowed by supply chain pressures; COVID-19 tests exceed expectations
The company raised its earnings forecast for 2022 on the back of an expected $7.8 billion in annual sales related to COVID-19 testing.
By Elise Reuter • Oct. 19, 2022 -
FDA seeks feedback on plans to draft and finalize medical device guidance in 2023
The agency’s review includes guidance on transitioning away from emergency use authorizations, while abandoning plans for guidance on software as a medical device.
By Nick Paul Taylor • Oct. 19, 2022